ACM
ONCT

ACT Capital Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

ACT Capital Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$187K Hold
10,500
– – 0.26% 38
2022
Q2 		$233K Sell
10,500
-750
-7% -$16.7K 0.33% 40
2022
Q1 		$313K Sell
11,250
-6,750
-38% -$246K 0.33% 44
2021
Q4 		$817K Hold
18,000
– – 0.59% 33
2021
Q3 		$1.5M Hold
18,000
– – 0.78% 31
2021
Q2 		$1.71M Buy
+18,000
New +$2.14M 0.88% 29

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $324M AUM 37.9% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ACT Capital Management's ONCT Position: Q3 2022 in Review

ACT Capital Management held its Oncternal Therapeutics, Inc. Common Stock (ONCT) position steady in Q3 2022 at 10,500 shares worth $187K. The position accounts for 0.26% of the portfolio, ranked #38.

ACT Capital Management first reported a position in ONCT in Q2 2021 and has held it in 6 quarters since. The position peaked at $1.71M in Q2 2021. 61 funds tracked by Wall St. Rank hold ONCT as of Q3 2022.

  • ACT Capital Management held 10,500 shares of Oncternal Therapeutics, Inc. Common Stock worth $187K as of Q3 2022.
  • ACT Capital Management left its Oncternal Therapeutics, Inc. Common Stock share count unchanged in Q3 2022.
  • Oncternal Therapeutics, Inc. Common Stock made up 0.26% of ACT Capital Management's portfolio in Q3 2022, its #38 holding.
  • ACT Capital Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2021 and has held it in 6 quarters since.
  • ACT Capital Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $1.71M in Q2 2021.
  • 61 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.